Select Publications
Journal articles
1993, 'Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response [1]', AIDS, 7, pp. 127 - 128, http://dx.doi.org/10.1097/00002030-199301000-00020
,1993, 'Chemotherapy made easier.', Australian and New Zealand journal of medicine, 23, pp. 387 - 392, http://dx.doi.org/10.1111/j.1445-5994.1993.tb01440.x
,1993, 'Effects of Cytokines on the Pituitary–Adrenal Axis in Cancer Patients', Journal of Interferon Research, 13, pp. 349 - 357, http://dx.doi.org/10.1089/jir.1993.13.349
,1993, 'Human recombinant interferon-β
1992, 'NOVEL APPROACHES TO THE MANAGEMENT OF GYNECOLOGIC MALIGNANCIES - CHAIRMENS PREFACE - PROCEEDINGS OF A SATELLITE SYMPOSIUM HELD IN CAIRNS, AUSTRALIA, ON 22 SEPTEMBER 1991', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2, pp. 1 - 1, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1992KF21500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1992, 'A phase II study of crisnatol mesylate in patients with ovarian carcinoma', Investigational New Drugs, 10, pp. 107 - 112, http://dx.doi.org/10.1007/BF00873127
,1992, 'Absence of Biological Effects of Orally Administered Interferon-β
1992, 'Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells', Journal of Clinical Oncology, 10, pp. 735 - 746
,1992, 'EVIDENCE THAT RECOMBINANT INTERFERONS CAN ENHANCE THE SENSITIVITY OF THE DETECTION OF SERUM TAG-72 AND CEA IN PATIENTS DIAGNOSED WITH ADENOCARCINOMA', Journal of Immunotherapy, 11, pp. 126 - 126, http://dx.doi.org/10.1097/00002371-199202000-00021
,1991, 'Evidence for the Elevation of Serum Carcinoembryonic Antigen and Tumor-associated Glycoprotein-72 Levels in Patients Administered Interferons', Cancer Research, 51, pp. 4155 - 4163
,1991, 'Advances in drug delivery and targeting', Current Opinion in Oncology, 3, pp. 1096 - 1104, http://dx.doi.org/10.1097/00001622-199112000-00019
,1991, 'Effects of interferon βser and transforming growth factor β on prostatic cell lines', Journal of Urology, 146, pp. 1173 - 1177, http://dx.doi.org/10.1016/S0022-5347(17)38034-5
,1991, 'Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinom', Cancer Investigation, 9, pp. 35 - 48, http://dx.doi.org/10.3109/07357909109032798
,1990, 'Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-α2', Breast Cancer Research and Treatment, 15, pp. 95 - 101, http://dx.doi.org/10.1007/BF01810781
,1990, 'Phase II trial of carboplatin in soft-tissue sarcoma', American Journal of Clinical Oncology: Cancer Clinical Trials, 13, pp. 420 - 423, http://dx.doi.org/10.1097/00000421-199010000-00011
,1990, 'Phase I studies of recombinant interferon-gamma.', J Biol Response Mod, 9, pp. 185 - 193, https://www.ncbi.nlm.nih.gov/pubmed/2160521
,1989, 'REPETITIVE WEEKLY CYCLES OF INTERLEUKIN-2 - EFFECT OF OUTPATIENT TREATMENT WITH A LOWER DOSE OF INTERLEUKIN-2 ON NON-MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED KILLER ACTIVITY', CANCER RESEARCH, 49, pp. 6832 - 6839, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1989CA66300061&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1989, 'Human biologic response modification by interferon in the absence of measurable serum concentrations: A comparative trial of subcutaneous and intravenous interferon-β serine', Journal of the National Cancer Institute, 81, pp. 1061 - 1068, http://dx.doi.org/10.1093/jnci/81.14.1061
,1989, 'Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells', Journal of the National Cancer Institute, 81, pp. 502 - 512, http://dx.doi.org/10.1093/jnci/81.7.502
,1989, 'Effects of Type I and II Interferons on Cultured Human Breast Cells: Interaction with Estrogen Receptors and with Tamoxifen', Cancer Research, 49, pp. 2698 - 2702
,1989, 'Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy', Oncology (Switzerland), 46, pp. 105 - 108, http://dx.doi.org/10.1159/000226695
,1988, 'The doctor's dilemma (the nurse's Waterloo)', Cancer Investigation, 6, pp. 361 - 363, http://dx.doi.org/10.3109/07357908809080660
,1988, 'The role of interferon in cancer therapy: A current perspective', CA: A Cancer Journal for Clinicians, 38, pp. 258 - 277, http://dx.doi.org/10.3322/canjclin.38.5.258
,1988, 'Contributions of benzodiazepines to cancer therapy.', Cancer Invest, 6, pp. 103 - 111, http://dx.doi.org/10.3109/07357908809077033
,1987, 'Chemotherapy influencing the course of nephrotic syndrome in colonic carcinoma', Medical Oncology and Tumor Pharmacotherapy, 4, pp. 101 - 105, http://dx.doi.org/10.1007/BF02934947
,1987, 'Effects of 7-Interferon on the Endocrine System: Results from a Phase I Study', Cancer Research, 47, pp. 6397 - 6401
,1986, 'Interferon Therapy in Cancer: From Imaginon to Interferon', Cancer Research, 46, pp. 4315 - 4329
,1986, 'Lymphokine‐induced monocyte procoagulant activity is depressed in patients with advanced malignancies', International Journal of Cancer, 37, pp. 677 - 682, http://dx.doi.org/10.1002/ijc.2910370506
,1986, 'Does maintenance therapy with alpha interferon stabilize cancer growth? A pilot study.', J Biol Response Mod, 5, pp. 294 - 299, https://www.ncbi.nlm.nih.gov/pubmed/3734845
,Conference Papers
2022, 'Patient vignettes reflecting the impact of The Australian Rare Cancer Portal on patients with Rare Cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 182 - 183, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000871956500292&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'CRO-67 is a novel therapeutic for pancreatic cancer: Implications for tumor and stromal reprogramming.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, pp. 161 - 161, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 13 September 2022 - 16 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000899825600205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'LONGITUDINAL TRAJECTORIES OF CLINICAL, NEUROLOGICAL AND PATIENT-REPORTED CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY FOLLOWING TREATMENT COMPLETION', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, pp. S169 - S169, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000822950200350&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'A PHASE IB EXPANSION COHORT OF PIXATIMOD PLUS NIVOLUMAB IN PREVIOUSLY TREATED, MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER (MSS MCRC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A367 - A367, http://dx.doi.org/10.1136/jitc-2021-SITC2021.341
,2021, 'A PHASE IB STUDY OF THE SAFETY AND TOLERABILITY OF PIXATIMOD PLUS NIVOLUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS WITH AN EXPANSION COHORT IN METASTATIC PANCREATIC ADENOCARCINOMA (MPDAC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A366 - A366, http://dx.doi.org/10.1136/jitc-2021-SITC2021.340
,2021, 'Delivering personalized care and research for rare cancers in the increasingly genomic world?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 92 - 92, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500102&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Effectively communicating comprehensive tumour genomic profiling results: Mitigating uncertainty for advanced cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 180 - 180, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500295&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Psychological outcomes in advanced cancer patients after receiving genomic tumour profiling results', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 198 - 198, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500332&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'The Australian Rare Cancer Portal: A retrospective review of referring oncologist's service requests', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 105 - 106, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500137&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'A psychometric comparison of three approaches to chemotherapy-induced peripheral neuropathy assessment: Patient report, clinical grading, and sensory function', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. S96 - S96, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000712224700205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1074 - S1074, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1547
,2021, 'Multifaceted approach to profiling vincristine-induced peripheral neuropathy', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, pp. 360 - 360, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000696233800123&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Hepatocyte growth factor/c-MET inhibition plus chemotherapy improves tumor immunity and eliminates metastasis in pancreatic cancer', Virtual, presented at Australian Gastroenterology Week, Virtual, 10 August 2021
,2021, 'HEPATOCYTE GROWTH FACTOR/ C-MET PATHWAY INHIBITION COMBINED WITH CHEMOTHERAPY RETARDS PRECURSOR PANINS AND POTENTIATES LOCAL IMMUNITY IN A TRANSGENIC MODEL OF EARLY PANCREATIC CANCER', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, ELECTR NETWORK, pp. S45 - S45, presented at Society-for-Surgery-of-the-Alimentary-Tract Annual Meeting at Digestive Disease Week (DDW), ELECTR NETWORK, 21 May 2021 - 23 May 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000649085000104&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Corneal inferior whorl morphology and reproducibility with in-vivo confocal microscopy in peripheral neuropathy', in INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, ELECTR NETWORK, presented at ARVO Imaging in the Eye Conference, ELECTR NETWORK, 13 May 2021 - 14 May 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000720324200022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, '184 HEPATOCYTE GROWTH FACTOR/ C-MET PATHWAY INHIBITION COMBINED WITH CHEMOTHERAPY RETARDS PRECURSOR PANINS AND POTENTIATES LOCAL IMMUNITY IN A TRANSGENIC MODEL OF EARLY PANCREATIC CANCER', in Gastroenterology, Elsevier BV, pp. S - 45, http://dx.doi.org/10.1016/s0016-5085(21)00855-6
,2021, 'Targeting the urokinase plasminogen activator (uPA) pathway inhibits pancreatic cancer progression', in Pancreatology, Elsevier BV, pp. S73 - S73, http://dx.doi.org/10.1016/j.pan.2021.05.196
,2020, 'How much do cancer patients value whole genome sequencing? A cross-sectional survey using the willingness-to-pay technique', in EUROPEAN JOURNAL OF HUMAN GENETICS, SPRINGERNATURE, pp. 790 - 790, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000598482602498&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Psychological impact of comprehensive genomic profiling results to advanced cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 92 - 92, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'The Australian Rare Cancer Portal - A national framework for co-ordinating streamlined access to rare cancer clinical expertise and research', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 206 - 206, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400327&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Pancreatic cancer-related diabetes: Do pancreatic stellate cell and cancer cell derived exosomes play a role?', in Pancreratology, presented at European Pancreatic Club
,